Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.
New research shows that treating these viruses can reduce liver cancer risk.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.